Literature DB >> 31005492

Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.

Kwonjune J Seung1, Cathy Hewison2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31005492     DOI： 10.1016/S2214-109X(19)30186-X

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN： 2214-109X            Impact factor:   26.763


× No keyword cloud information.
  4 in total

Review 1.  Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

Authors:  Daniélle van Staden; Richard K Haynes; Joe M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-06-15

2.  Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.

Authors:  Philipp du Cros; Atadjan Khamraev; Zinaida Tigay; Tleubergen Abdrasuliev; Jane Greig; Graham Cooke; Krzysztof Herboczek; Tanya Pylypenko; Catherine Berry; Amrita Ronnachit; David Lister; Sebastian Dietrich; Cono Ariti; Khasan Safaev; Bern-Thomas Nyang'wa; Nargiza Parpieva; Mirzagalib Tillashaikhov; Jay Achar
Journal:  ERJ Open Res       Date:  2021-02-08

3.  An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor.

Authors:  Eva Habjan; Vien Q T Ho; James Gallant; Gunny van Stempvoort; Kin Ki Jim; Coen Kuijl; Daan P Geerke; Wilbert Bitter; Alexander Speer
Journal:  Dis Model Mech       Date:  2021-12-23       Impact factor: 5.758

4.  The Discovery and Structure-Activity Evaluation of (+)-Floyocidin B and Synthetic Analogs.

Authors:  Yolanda Kleiner; Christoph Pöverlein; Jannike Klädtke; Michael Kurz; Henrik F König; Jonathan Becker; Sanja Mihajlovic; Florian Zubeil; Michael Marner; Andreas Vilcinskas; Till F Schäberle; Peter Hammann; Sören M M Schuler; Armin Bauer
Journal:  ChemMedChem       Date:  2021-11-17       Impact factor: 3.540
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.